BioCentury | Jun 16, 2017
Financial News

Sygnis raises EUR10M in rights offering and private placement to fund Innova acquisition

...Molecular biology services company Sygnis AG (Xetra:LIO1) raised €10 million ($11.2 million) across two offerings in...
...through the sale of 3.7 million shares at the same price in a private placement. Sygnis...
...officer, will join Sygnis as chief technical officer. Sygnis AG (Xetra:LIO1), Heidelberg, Germany Julian Zhu Innova Biosciences Ltd. Sygnis...
BioCentury | Jul 25, 2016
Financial News

Sygnis completes private placement

Sygnis AG (Xetra:LIO1), Heidelberg, Germany Business: Genomics, Supply/Service Date completed: 2016-07-14 Type: Private placement Raised: EUR2 million ($2.2 million) Shares: 1.8 million Price: EUR1.10 Shares after offering: 37.3 million Investor: Institutional investors Note: The shares...
BioCentury | Jul 25, 2016
Financial News

Sygnis completes rights offering

Sygnis AG (Xetra:LIO1), Heidelberg, Germany Business: Genomics, Supply/Service Date completed: 2016-07-14 Type: Rights offering Raised: EUR3.3 million ($3.7 million) Shares: 3 million Price: EUR1.10 Shares after offering: 37.3 million Investor: Existing investors Note: The shares...
BioCentury | Dec 14, 2015
Financial News

Sygnis Pharma completes rights offering

...3 million Price: EUR1.90 Shares after offering: 16.8 million Investors: Existing investors; institutional investors Note: Sygnis...
BioCentury | Nov 23, 2015
Financial News

Sygnis Pharma proposes rights offering

...every seven held. Under the offering, shareholder Genetrix may acquire up to EUR600,000 ($644,400) in Sygnis...
BioCentury | Jun 4, 2015
Company News

Management tracks

...India). Oncology company Apogenix GmbH (Heidelberg, Germany) named Peter Willinger CFO. He was CFO of Sygnis Pharma...
BioCentury | Dec 22, 2014
Financial News

Sygnis Pharma completes rights offering

Sygnis Pharma AG (Xetra:LIO1), Heidelberg, Germany Business: Genomics, Supply/Service Date completed: 2014-12-12 Type: Rights offering Raised: EUR5 million ($6.2 million) Shares: 2.5 million Price: €2 Shares after offering: 13.2 million Investor: Existing investors Note: Shareholders...
BioCentury | May 19, 2014
Company News

Sygnis Pharma, Systasy deal

...Systasy acquired patents covering Sygnis' Split-TEV Double Switch technology. The IP is part of a broader...
...of two proteins. The technology is based on the tobacco etch virus (TEV) protease, which Sygnis...
...or in a split version (Split-TEV) to detect protein-protein interactions in a "highly sensitive manner." Sygnis...
BioCentury | Mar 17, 2014
Finance

Circassia raises expectations

...billion). No European biotech IPO has come close to the Circassia deal since 2000, when Lion bioscience...
...IPO on Xetra. After selling off its bioinformatics assets, Lion was reincarnated in 2006 as Sygnis Pharma...
...Group plc (LSE:RNVO), Manchester, U.K. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Stallergenes S.A. (Euronext:GENP), Antony, France Sygnis Pharma...
BioCentury | Dec 23, 2013
Financial News

Sygnis Pharma completes rights offering

...€400,741 ($551,219) Shares: 151,223 Price: €2.65 Shares after offering: 10.5 million Investors: Existing investors Note: Sygnis...
Items per page:
1 - 10 of 282
BioCentury | Jun 16, 2017
Financial News

Sygnis raises EUR10M in rights offering and private placement to fund Innova acquisition

...Molecular biology services company Sygnis AG (Xetra:LIO1) raised €10 million ($11.2 million) across two offerings in...
...through the sale of 3.7 million shares at the same price in a private placement. Sygnis...
...officer, will join Sygnis as chief technical officer. Sygnis AG (Xetra:LIO1), Heidelberg, Germany Julian Zhu Innova Biosciences Ltd. Sygnis...
BioCentury | Jul 25, 2016
Financial News

Sygnis completes private placement

Sygnis AG (Xetra:LIO1), Heidelberg, Germany Business: Genomics, Supply/Service Date completed: 2016-07-14 Type: Private placement Raised: EUR2 million ($2.2 million) Shares: 1.8 million Price: EUR1.10 Shares after offering: 37.3 million Investor: Institutional investors Note: The shares...
BioCentury | Jul 25, 2016
Financial News

Sygnis completes rights offering

Sygnis AG (Xetra:LIO1), Heidelberg, Germany Business: Genomics, Supply/Service Date completed: 2016-07-14 Type: Rights offering Raised: EUR3.3 million ($3.7 million) Shares: 3 million Price: EUR1.10 Shares after offering: 37.3 million Investor: Existing investors Note: The shares...
BioCentury | Dec 14, 2015
Financial News

Sygnis Pharma completes rights offering

...3 million Price: EUR1.90 Shares after offering: 16.8 million Investors: Existing investors; institutional investors Note: Sygnis...
BioCentury | Nov 23, 2015
Financial News

Sygnis Pharma proposes rights offering

...every seven held. Under the offering, shareholder Genetrix may acquire up to EUR600,000 ($644,400) in Sygnis...
BioCentury | Jun 4, 2015
Company News

Management tracks

...India). Oncology company Apogenix GmbH (Heidelberg, Germany) named Peter Willinger CFO. He was CFO of Sygnis Pharma...
BioCentury | Dec 22, 2014
Financial News

Sygnis Pharma completes rights offering

Sygnis Pharma AG (Xetra:LIO1), Heidelberg, Germany Business: Genomics, Supply/Service Date completed: 2014-12-12 Type: Rights offering Raised: EUR5 million ($6.2 million) Shares: 2.5 million Price: €2 Shares after offering: 13.2 million Investor: Existing investors Note: Shareholders...
BioCentury | May 19, 2014
Company News

Sygnis Pharma, Systasy deal

...Systasy acquired patents covering Sygnis' Split-TEV Double Switch technology. The IP is part of a broader...
...of two proteins. The technology is based on the tobacco etch virus (TEV) protease, which Sygnis...
...or in a split version (Split-TEV) to detect protein-protein interactions in a "highly sensitive manner." Sygnis...
BioCentury | Mar 17, 2014
Finance

Circassia raises expectations

...billion). No European biotech IPO has come close to the Circassia deal since 2000, when Lion bioscience...
...IPO on Xetra. After selling off its bioinformatics assets, Lion was reincarnated in 2006 as Sygnis Pharma...
...Group plc (LSE:RNVO), Manchester, U.K. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Stallergenes S.A. (Euronext:GENP), Antony, France Sygnis Pharma...
BioCentury | Dec 23, 2013
Financial News

Sygnis Pharma completes rights offering

...€400,741 ($551,219) Shares: 151,223 Price: €2.65 Shares after offering: 10.5 million Investors: Existing investors Note: Sygnis...
Items per page:
1 - 10 of 282